Tag: NEOVACS
NEOVACS: 2 MEUR FUND RAISING – 2022/10/31 at 7:00 pm
Paris, October 31, 2022 – 7:00 p.m. CET – Néovacs (Euronext Growth Paris: ALNEV) announces a fundraising of €2 million through the drawdown of 2 tranches of OCEANE-BSA bonds, with…
NEOVACS: 2022 HALF-YEAR RESULTS: ACCELERATION OF THE STRATEGIC ROADMAP IN RESPECT OF COMMITMENTS MADE – 2022/10/31 at 19:15
Paris, October 31, 2022 – 7:15 p.m. CET – Neovacs (Euronext Growth Paris: ALNEV) announces its 2022 half-year results. The half-year financial report is made available to the public today…
Pharnext signs a financing agreement with Néovacs for a net amount of 20.7 million euros allowing the continuation of the development of PXT3003 in Charcot-Marie-Tooth disease type 1A – 10/03/2022 at 18:00
• At the end of this financing program, carried out via the issue in several tranches of simple bonds for a total nominal amount of approximately 21 million euros (i.e.…
Néovacs: Leaves the recovery plan 8 years in advance
Receive the value of the day selected by The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its…
Neovacs: 8 years in advance, biotech Neovacs completes its recovery plan
(BFM Bourse) – The biotechnology company specializing in the fight against autoimmune diseases has repaid all of the liabilities that had been stopped in this recovery plan. In response, the…
NEOVACS: NEOVACS REIMBURSED ENTIRE LIABILITIES CLOSED AS PART OF THE CONTINUTATION PLAN 8 YEARS IN ADVANCE – 08/22/2022 at 08:00
Paris, August 22, 2022 – 8 a.m. CET – Néovacs (Euronext Growth Paris: ALNEV) announces the closure of the recovery plan implemented in May 2020, 8 years ahead of the…
Neovacs: leaves the recovery plan 8 years in advance
(CercleFinance.com) – Néovacs announces the closure, 8 years ahead of the schedule set by the Paris Commercial Court, of the recovery plan implemented in May 2020. This exceptional decision was…
Néovacs: leaves the recovery plan 8 years in advance – 08/22/2022 at 10:00 am
(CercleFinance.com) – Néovacs announces the closure, 8 years ahead of the schedule set by the Paris Commercial Court, of the recovery plan implemented in May 2020. This exceptional decision was…
Neovacs plans to invest in Pharnext to fund the pivotal phase III study of PXT3003 in Charcot’s disease
By Claude Leguilloux Published on 08/08/2022 at 08:07 Photo credit © Reuters (Boursier.com)…
NEOVACS: NEOVACS PLANS TO INVEST IN PHARNEXT TO FUND PIVOT PHASE III CLINICAL STUDY OF PXT3003 IN CHARCOT-MARIE-TOOTH DISEASE TYPE 1A – 08/08/2022 at 08:00
Paris, August 8, 2022 – 8 a.m. CET – Neovacs (Euronext Growth Paris: ALNEV) announces that it has entered into negotiations with the company Pharnext (Euronext Growth Paris: ALPHA) in…
Neovacs: in negotiation with Pharnext for an investment – 08/08/2022 at 10:09
(CercleFinance.com) – Neovacs announces that it has entered into negotiations with Pharnext in order to support this biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases…
Neovacs: in negotiation with Pharnext for an investment
(CercleFinance.com) – Neovacs announces that it has entered into negotiations with Pharnext in order to support this biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases…